NTxBio
PrivateLast Round
Grant
May 14, 2025
Total Funding Raised
$77.32M
Company Overview
NTxBio operates in Healthcare & Life Sciences and is based in Rio Rancho, New Mexico. Its latest recorded funding round was a Grant round in May 2025.
NTxBio is a biotechnology company that provides a cell-free biomanufacturing platform for the scalable production of high-quality RNA and protein therapeutics.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Biotech Equipment, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting, Government Contracts, Hardware Sales
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
NTxBio Comparables
Compare NTxBio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Waterfall Scientific | 84% | |
| Tierra Biosciences | 79% | |
| Liberum Biotech | 79% |
For institutional investors. Book with your work email.
NTxBio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | May 14, 2025 | ||||
| Debt | Dec 4, 2024 | ||||
| Series B | Nov 16, 2023 | ||||
| Grant | Feb 25, 2020 | ||||
| Series A | Feb 25, 2020 |
For institutional investors. Book with your work email.
NTxBio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| RA Capital Management | Series A, Series B |
| Texas Enterprise Fund | Grant |
| New Mexico Economic Development Department | Grant |
| Anzu Partners | Series B, Series A |
| New Mexico Economic Development Department | Grant |
| BlueStone Venture Partners | Series B |
| JPMorgan Chase & Co. | Debt |
Market signals
Structured signals derived from secondary market and firmographic data.
- May 15, 2025
Opening a new $31 million facility and adding 170 jobs in Texas.
- May 14, 2025
$1.48M grant from Texas Enterprise Fund
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- is_developingAug 19, 2026
Based in New Mexico, Ntxbio is developing NTxscribe(R) and NTxpress(R) systems to enable sustainable RNA and protein therapeutics production at scales ranging from personalized doses to mass-market volumes.
For institutional investors. Book with your work email.
NTxBio Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about NTxBio's valuation, stock price, and market status.
Is NTxBio a public or private company?
NTxBio is a private company.
What is the current stock price of NTxBio?
NTxBio is a private company, so its shares have no public market price. Caplight tracks NTxBio's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is NTxBio worth (valuation)?
Valuation information for NTxBio is not publicly available.
Can I buy NTxBio stock?
NTxBio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was NTxBio's last funding round?
NTxBio's most recent funding round was Grant on May 14, 2025.
Who are the main investors in NTxBio?
Key investors in NTxBio include RA Capital Management, Anzu Partners, JPMorgan Chase & Co..
Will NTxBio IPO soon?
No public IPO plans have been announced for NTxBio.
How can I track NTxBio secondary market activity?
Caplight tracks bids, offers, and trades in NTxBio's shares on secondary markets.